Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers at UCSF has found. The strategy could also help stop the spread of HIV by keeping more patients from being infectious. In 2021, federal regulators approved the first long-acting antiretroviral (LA-ART) injectable, which is a combination of long-acting cabotegravir and rilpivirine. But they only approved it for HIV patients who already had their infections under control with pills.